The first approach to treatment is essential. Cure is the main goal, and is considered as important as the quality of life and functionality of the treated organs, such as the voice, language, swallowing, taste and breathing. IEO provides patients with a multidisciplinary team dedicated to diagnosis, treatment and rehabilitation
THE VALUE OF A MULTIDISCIPLINARY TEAM
Our multidisciplinary team is dedicated to the diagnosis, treatment and rehabilitation of patients with tumors of the head and neck, and to the study of these diseases. Our team includes over thirty oncology professionals with expertise in various specialties, such as ENT, maxillofacial surgery, emergency surgery, plastic-reconstructive surgery, radiotherapy, medical oncology, radiology, pathology, nuclear medicine, nutrition, physiotherapy, endocrinology, dentistry, voice therapy, speech therapy, psychology, and biology.
The integration of various skills can address complex clinical problems, from diagnosis and treatment planning, to the functional recovery (speech, breathing, swallowing) in order to achieve the best results with cancer and ensure an adequate quality of life. The team works in harmony and meets on a weekly basis to discuss cases of the patients in our trust. They develop comprehensive personalized care plans considering all aspects of treatment and rehabilitation, looking at the different treatment options, and taking into account the needs of individual patients in accordance with internal, national and international guidelines.
The team, in close collaboration with the Scientific and Health Management Board, monitors the results of treatment and the quality of the performances in real time in order to point out critical issues and identify areas for improvement and development. The multidisciplinary meetings are an opportunity for professional development based on the exchanges in the group, the evidence in the literature, and the critical review and update of guidelines as well as diagnostic and therapeutic approaches. The information obtained from the critical review of the clinical activities, from technological innovations, from the study of the evolution of the cancers treated, and from continuous updating are used to identify open issues and propose research activities. Thanks to this approach, clinical research activities and institutional research projects in collaboration with national and international institutions have been put in place.
Cancers of the skin and face
Removing a tumour of the face almost always requires a combined approach of curative surgery and reconstructive surgery; consider the importance of proper closing of the eyelids to protect the eye, or the function of the lips for speech and mastication, or the nose for breathing.
Advanced tumours may require the intervention of the cervical-facial surgeon. This may be necessary when the tumour invades bone structure (jaw, cheekbone) or when infiltrating the skin it comes to affect the internal mucous membranes (cheek, nose). Some advanced tumours (such as spinal cell carcinomas) can cause metastases in the parotid gland or lymph nodes in the neck. In these cases, it may be necessary to add parotidectomy or lateral-cervical lymphadenectomy to the intervention for tumour removal.
Distant metastases of head and neck carcinoma
Distant metastases are defined as tumor spread to other organs. Lung, liver, and bone are the most common sites for hematogenous metastases of head and neck squamous cell carcinoma. The incidence of distant metastasis in head and neck squamous cell carcinoma is low for the general head and neck squamous cell carcinoma population: generally below 5% at presentation. Head and neck squamous cell carcinoma patients with distant metastases are generally candidates for palliative treatment scenarios only, because currently no systemic therapy has curative potential in head and neck squamous cell carcinoma patients with distant disease. Consequently, extensive locoregional treatment is usually considered futile in these patients. Particular attention is paid to our collaboration with CNAO, National Centre of Oncology Hadrontherapy) for Phase II, the clinical trial on radiotherapy boost, using protons (hadron therapy) for locally advanced tumours of the cervical-cephalic region.